ES2155472T3 - NEW POLYPEPTIDE WITH INHIBITING ACTIVITY OF FACTOR XA. - Google Patents

NEW POLYPEPTIDE WITH INHIBITING ACTIVITY OF FACTOR XA.

Info

Publication number
ES2155472T3
ES2155472T3 ES94914087T ES94914087T ES2155472T3 ES 2155472 T3 ES2155472 T3 ES 2155472T3 ES 94914087 T ES94914087 T ES 94914087T ES 94914087 T ES94914087 T ES 94914087T ES 2155472 T3 ES2155472 T3 ES 2155472T3
Authority
ES
Spain
Prior art keywords
polypeptide
factor
inhibiting activity
new polypeptide
deposited
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94914087T
Other languages
Spanish (es)
Inventor
Elisha P Zeelon
Moshe M Werber
Avigdor Levanon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Savient Pharmaceuticals Inc
Original Assignee
Savient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals Inc filed Critical Savient Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2155472T3 publication Critical patent/ES2155472T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/57Protease inhibitors from animals; from humans
    • A61K38/58Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/815Protease inhibitors from leeches, e.g. hirudin, eglin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A novel polypeptide derived from the leech Hirudo medicinalis was found to be able to inhibit Factor Xa thereby reducing the extent of blood coagulation. The polypeptide is useful in treating conditions of excessive blood coagulation. A recombinant organism containing cDNA encoding the polypeptide has been deposited in the ATCC under Accession No. 69134. Recombinant microorganisms able to produce the polypeptide have been deposited in the ATCC under Accession Nos. 69135, 69137 and 69269.
ES94914087T 1993-04-09 1994-04-08 NEW POLYPEPTIDE WITH INHIBITING ACTIVITY OF FACTOR XA. Expired - Lifetime ES2155472T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4580593A 1993-04-09 1993-04-09

Publications (1)

Publication Number Publication Date
ES2155472T3 true ES2155472T3 (en) 2001-05-16

Family

ID=21939985

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94914087T Expired - Lifetime ES2155472T3 (en) 1993-04-09 1994-04-08 NEW POLYPEPTIDE WITH INHIBITING ACTIVITY OF FACTOR XA.

Country Status (14)

Country Link
EP (1) EP0696198B1 (en)
JP (1) JPH08511157A (en)
KR (1) KR960701649A (en)
AT (1) ATE198710T1 (en)
AU (1) AU682361B2 (en)
CA (1) CA2159218A1 (en)
DE (1) DE69426598T2 (en)
DK (1) DK0696198T3 (en)
ES (1) ES2155472T3 (en)
GR (1) GR3035722T3 (en)
IL (1) IL109259A0 (en)
NZ (1) NZ265507A (en)
PT (1) PT696198E (en)
WO (1) WO1994023735A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2158923B1 (en) 1998-08-06 2013-02-27 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
WO2008051178A2 (en) 2006-04-12 2008-05-02 Savient Pharmaceuticals, Inc. Purification of proteins with cationic surfactant
DK3321359T3 (en) 2005-04-11 2021-03-08 Horizon Pharma Rheumatology Llc VARIANT FORMS OF URATOXIDASIS AND ITS USE
CN102807973A (en) 2005-04-11 2012-12-05 萨文特医药公司 A variant form of urate oxidase and use thereof
RU2535038C2 (en) 2009-06-25 2014-12-10 Криэлта Фармасьютикалз ЭлЭлСи Methods and sets for predicting risk of infusion responses and antibody-mediated loss of response in therapy with pegylated uricase by monitoring uric acid content in blood serum
US8685462B1 (en) 2012-09-17 2014-04-01 Biopep Solutions, Inc. Whole, leech saliva product and applications thereof
EP3538135A4 (en) 2016-11-11 2020-07-29 Horizon Pharma Rheumatology LLC COMBINATION THERAPIES OF PREDNISON AND URICASE MOLECULES AND THEIR USE
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588587A (en) * 1983-03-01 1986-05-13 Pennsylvania Hospital Method of treatment to inhibit metastasis
DE58907266T2 (en) * 1988-06-11 1994-09-29 Ciba Geigy Ag Polypeptides with an anti-coagulation effect.
US4832849A (en) * 1988-06-16 1989-05-23 Merrell Dow Pharmaceuticals Inc. Extraction and purification of an anticoagulant principle from the south american leech, haementeria ghilianii
IL86856A0 (en) * 1988-06-24 1988-11-30 Yissum Res Dev Co Bovine xa factor and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
IL109259A0 (en) 1994-07-31
DK0696198T3 (en) 2001-08-06
WO1994023735A1 (en) 1994-10-27
NZ265507A (en) 1998-09-24
JPH08511157A (en) 1996-11-26
KR960701649A (en) 1996-03-28
EP0696198B1 (en) 2001-01-17
HK1013315A1 (en) 1999-08-20
DE69426598T2 (en) 2001-08-09
PT696198E (en) 2001-07-31
EP0696198A4 (en) 1999-01-27
EP0696198A1 (en) 1996-02-14
CA2159218A1 (en) 1994-10-27
GR3035722T3 (en) 2001-07-31
AU6629194A (en) 1994-11-08
AU682361B2 (en) 1997-10-02
ATE198710T1 (en) 2001-02-15
DE69426598D1 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
OA09711A (en) Epithelins: novel cysteine-rich growth modulating proteins.
IL109259A0 (en) Novel polypeptide having factor Xa inhibitory activity
PL309398A1 (en) Interferon containing therapeutic composition
GEP20033145B (en) Stem Cell Factor
PT86381A (en) Molecular cloning and expression of human il-3
BG99054A (en) Mycobacterium vaccae for the treatment of continuous autoimmune conditions
NZ506135A (en) Monocyte colony inhibitory factor (M-CIF) derivatives and their use in treating sepsis
PL307258A1 (en) Peptides capable to block calcium canals with agelenopsis aperta
DE69224237D1 (en) Lactococcus lactis bacteriocin subspecies Lactis
TW327627B (en) Water purification material, process of preparation thereof and water purification unit
EP0460072A4 (en) Human elastase inhibitor
DE69004794D1 (en) Use of a polypeptide with interleukin 2 activity for the manufacture of a pharmaceutical composition intended for the treatment of simple pleural ulcers.
AU1909995A (en) Co-administration of interleukin-3 mutant polypeptides with csf's for multi-lineage hematopoietic cell production
CA2004202A1 (en) Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
Rawczynska-Englert et al. Staphylococcal endocarditis after valve replacement(9 years of experience).
EP0181524A3 (en) Novel lymphokine
UA7184C2 (en) M. shportiuk contact technique for decreasing arterial pressure
SU1593010A1 (en) METHOD FOR ACTIVATING CATALYST FOR DEGYDURING N-BUTEN
EP0331493A3 (en) Medical devices made from poly(etherimides)
WO1994021273A3 (en) USE OF ANGIOGENINE, AND/OR α1-MICROGLOBULINE AND/OR COMPLEMENTARY FACTOR D FOR LIMITING PROTEIN SECRETION
UA29617A (en) Method for obtained of antimicrobial phytopreparation with interferoninduce activity

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 696198

Country of ref document: ES